Iwamoto, S., Ooki, A., Morita, S., Hara, H., Tanioka, H., Satake, H., Kataoka, M., Kotaka, M., Kagawa, Y., Nakamura, M., Shingai, T., Ishikawa, M., Miyake, Y., Sudo, T., Hashiguchi, Y., Yabuno, T., Sakamoto, J., Tsuji, A., Ando, M., & Yamaguchi, K. (n.d.). a prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial. Cancer medicine, 7, 4217–4227. http://access.bl.uk/ark:/81055/vdc_100069102844.0x000008